Dutch biotech raises €30M for upscaled manufacturing, pilot study of blood clotting drug
VarmX, a Dutch biotech developing a reversal agent for blood thinners, has bagged a €30 million Series B2 round as it gets ready to launch a pivotal trial.
Spun out of the lab of founder Pieter Reitsma at Leiden University Medical Center, the company’s lead compound, VMX-C001, is designed to reverse the effects of cardiovascular drugs that prevent blood clots — so that patients who are on those drugs can stop bleeding when they need to.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters